{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-040546","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2023-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.012748+00:00","generated_at":"2026-06-07T18:46:52.166007+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Absci announces up to $247M AI antibody collaboration with AstraZeneca for oncology target","bullets":["Absci to apply its generative AI antibody platform to design an oncology candidate for AstraZeneca.","Total deal consideration up to $247M, including upfront, R&D funding, milestones, plus royalties on sales.","Agreement combines Absci's Integrated Drug Creation platform with AstraZeneca's oncology expertise.","Platform aims to reduce drug design-validation cycle to ~6 weeks and expand target universe to GPCRs, ion channels.","Collaboration follows Absci's recent publication on 'zero-shot' generative AI model for de novo antibody design."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-040546","json":"https://secwatch.observer/filing/0001628280-23-040546.json","markdown":"https://secwatch.observer/filing/0001628280-23-040546.md","text":"https://secwatch.observer/filing/0001628280-23-040546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828023040546/0001628280-23-040546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828023040546/absc-20231204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:46:52.166007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}